Minimally invasive therapy for benign prostatic hyperplasia (BPH) linked with lower urinary tract symptoms had gained popularity in the previous decade (LUTS). The temporary implanted nitinol device (iTIND) (Medi-Tate®; Medi-Tate Ltd., Or Akiva, Israel) was one of the current alternatives in this sector. For a study, the researchers evaluated the most recent research on the use of the first-generation (TIND) and second-generation (iTIND) devices in the management of BPH with LUTS, with a particular focus on the functional results.

Clinical trials on the issue were examined in PubMed, Embase, and the Cochrane Central Register of Controlled Trials. There was a paucity of data in the literature for TIND and iTIND implantation in PBH with LUTS. Only three studies were available for the research, one of which had a medium-term follow-up. The findings of the trials showed that TIND and iTIND implantations were both safe, effective, as well as well-tolerated treatments that allowed sexually active individuals to have spare ejaculation.

The temporarily implanted nitinol devices acted as promising alternatives to the usual minimally invasive surgical procedures for BPH-related LUTS, according to the current research. More research on the respected area was needed to prove its usefulness over a lengthy period of time.